With an influx of funding, Science 37 brings new hires to leadership and promotes from within to scale executive team for its next big phase of development
PLAYA VISTA, Calif. (July 5, 2017) – Science 37, an innovative company focused on making “site-less” clinical trials available to the masses, announced the recent hire of Joseph “Jay” Trepanier as Chief Operations Officer (COO,) as well as the addition of several new members of the leadership team with Susan Ko, Vice President of People, Amit Rushi, Vice President of Strategy, Informatics and Business Information, Audrey Cavenecia, Vice President of Media and Marketing, and Christopher Ceppi, Vice President of Product. These recent hires come on the heels of Science 37’s Series C funding announcement, and the internal promotion of other key staff members to strengthen the leadership team.
As COO, Trepanier will be responsible for driving growth and profitability as the company expands within the focus therapeutic areas of Dermatology, Oncology, Neurology, Psychiatry, and Diabetes. Former CEO of Clinverse, Inc., a specialty clinical service provider, Trepanier brings more than 25 years of operation, financial and commercial leadership experience to Science 37, including work with Alphanumeric Systems, Inc., Etrials and DataFlux. He has served on the board of directors at University of North Carolina Children’s Hospital, and holds an MBA as well as CPA license with certifications in project management and Six Sigma.
“Patients and families rely on clinical research to test and approve medicines that will slow or cure diseases. Science 37 is disrupting the clinical trial approach by accelerating the development of new drugs and devices through its proprietary Metasite™ approach,” said Trepanier. “The success of the Science 37 model has dramatically accelerated clinical trial timelines and has reduced costs to sponsors. My focus as Chief Operating Officer is to implement a scalable infrastructure as we enter into this next phase of rapid growth.”
Chris Ceppi was brought on as the new Vice President of Product at Science 37 to manage team, design, vision, and strategy of the proprietary Science 37 technology ecosystem. Prior to joining the team, Ceppi helped several startups drive innovative solutions into new markets and has also participated in successful IPOs and company acquisitions, at Sagent, Oblix (acquired by Oracle in 2005), and Ping Identity (acquired by Vista Equity Partners in 2016) where he held a position as Director of Strategic Alliance and Corporate Development since 2004. Ceppi holds a BA in English from University of California, Berkeley.
Susan Ko, PhD, joins the team as Vice President of People, overseeing the corporate culture of Science 37 including talent acquisition, cultivation and strategy. Dr. Ko’s more than 15 years of experience as a clinical psychologist in organizational transformation, talent assessment and leadership development will play an integral role in ensuring that a formative tenant of Science 37, success beginning with the people and culture of the company, will continue to foster growth in the company. Dr. Ko holds an MA and PhD in clinical philosophy from the University of Massachusetts at Boston, and a BS from Brown University.
Audrey Cavenecia is the new Vice President of Media and Marketing. Her primary role at Science 37 will be that of brand strategist and video content producer to create an environment, a culture – of scientists as storytellers, a platform for diversity and inclusion in research and a vision for science to be seen as, awesome. Over the past ten years, Cavenecia has achieved efficient marketing and branding solutions through cinema and community building. In her previous work as Creative Media Director of Colorful Media (formerly Infidea) she led storytelling campaigns for BMW, LA Children’s Hospital, and Four Seasons hotel group.
In addition to the new hires, Science 37 also recently advanced existing team members to elevated positions with the promotions of Marcella Debidda to Vice President of Patient Affairs, Alissa Kugler to Vice President of Strategic Alliances and David Marr to Vice President of Sales.
“We formed Science 37 as a team of academics and scientists to accelerate the process of biomedical research while putting patients first. Now that we’ve proven our model, interest in applying it to more therapeutic areas is growing exponentially as are our management team needs,” said Noah Craft, MD, PhD, co-founder and CEO of Science 37. “These key additions to our leadership team will help strengthen the existing core and allow us to continue to place solid structural elements in place as we grow, ensuring we can continue our approach to clinical trials in an innovative and properly scaled manner.”
Science 37’s core offering is focused on making clinical trials better for patients using their proprietary metasite™ and technology platform, the Network Oriented Research Assistant (NORA®) that patients can access from the comfort of their homes. The metasite™ decentralizes trials, enabling patients to participate regardless of their geographical location using study mobile devices and telemedicine services, and includes Virtual Trial Specialists, mobile nursing companies when needed, and study monitors to execute end-to-end clinical trial services for sponsors.
About Science 37
Science 37 is a Los Angeles-based technology-enabled clinical research company. They created a new clinical trial operating model – the metasite™ – that unlocks access so researchers can find the right patients, and patients can find the right trials. Their Network Orientated Research Assistant, NORA®, is the cloud-based patient-centric mobile research platform that connects everyone – safely and securely. Science 37 offers end-to-end clinical trial services without geographic limitations, making clinical research faster to accelerate biomedical discovery. Ultimately, Science 37 enables better, faster people-powered science and brings clinical trials to scale. Learn more at http://science37.com, and follow Science 37 on Twitter @Science_37.